Work

A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours

Year: 2015

Type: article

Study design: Clinical Trial

Source: European Journal of Cancer

DOI: 10.1016/j.ejca.2015.07.041

Authors: A. Suder, J.E. Ang, F. Kyle, D. Harris, S. Rudman, R. Kristeleit, F. Solca, M. Uttenreuther-Fischer, K. Pemberton, K. Pelling, D. Schnell, J. de Bono, J. Spicer

Institutions: Guy's Hospital, Guy's and St Thomas' NHS Foundation Trust, Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Boehringer Ingelheim (Austria), Boehringer Ingelheim (Germany), Boehringer Ingelheim (United Kingdom), King's College London

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W2137070812

FWCI: 2.038

Cites: 35

Cited by: 29

Related to: 10